// STATE LEGISLATION TRACKER

Michigan SB 94: Health: pharmaceuticals; drug manufacturers from engaging in certain conduct with pharmacies participating with a 340B p

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Passed chamber

State: Michigan
Bill: SB 94
Session: 2025-2026
Filed: 2025-02-20
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Michigan SB94 is a 340B pharmacy access and drug-price reporting bill, not a peptide, compounding, telehealth, or scope-of-practice bill. Based on the title, subjects, and available status, it does not appear to change access to compounded peptides, off-label prescribing, 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No direct change to compounded peptide access
No visible change to telehealth prescribing rules
No visible change to NP or naturopath scope
No peptide-specific 503A or 503B compounding rule
Main effect is on 340B drug access and reporting

What to Watch For

Note Watch whether later amendments add pharmacy, compounding, or prescribing language.

✓

Opportunity May help 340B clinics and contract pharmacies maintain access to covered outpatient drugs.

Note The bill is tied to SB95, so movement may depend on that related hospital transparency bill.

Where the Bill Stands

The bill passed the Michigan Senate on March 6, 2025, and was referred to the House Committee on Health Policy.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws